China Medical Systems of Shenzhen announced a $70-plus million agreement for China rights to a clinical-stage thrombotic drug from France’s Acticor Biotech. ACT017 is a humanized monoclonal antibody fragment (Fab) directed against a platelet glycoprotein (GPVI) involved in thrombosis, intended to treat stroke and pulmonary embolism. Part of the $70 million will be invested in an Acticor subsidiary. CMS will have development, manufacturing and commercialization rights to ACT017 in China and Asia (except for Japan and India).
Source: China Biotoday
